John-Paul Gallivan

• Leading cross-functional project teams for clinical and pre-clinical assets • Identification and evaluation of indications for all NuCana product candidates • Point of contact for NuCana with academic and industry drug discovery partners • Investor relations and financing activities • Partnering and business development • Responsible for maintenance and development of NuCana’s IP portfolio • Involvement in litigation regarding patent infringement • Development of commercialization strategies

• Contribution to all aspects of clinical development for NuCana’s assets at a time when no CMO was in place • Leading COVID therapy research and clinical development planning • Contribution to regulatory activities including development of regulatory strategy and interactions with regulators • Leading the medical team and responsible for all medical activities • Lead for commercial activities including forecasting, pricing and market research

• Leading and motivating a group of medical affairs directors with responsibilities for development and execution of medical affairs plans in breast cancer, tumour agnostic indications and personalized medicine • Coaching, developing and mentoring line reports (seven reports in total) and ensuring optimal hiring and retention • Collaboration and partnering with medical societies including ASCO, ESMO, ECC and NCCN on a range of topics (guideline updates, educational initiatives, physician burnout) • Development and implementation of novel methods to measure the impact of medical activities (clinical studies, insight gathering and education) and allow for better prioritization of resources

• Development and implementation of scientific communications strategy and tactical plan for Tecentriq breast cancer to support pre-launch activities • Responsible for planning and implementation of scientific communication activities to support Herceptin and Avastin breast cancer as part of lifecycle activities • Development of process for collecting insights obtained by medical colleagues in the field relevant to the breast cancer disease area

• Support of the International Project Leader in the leadership of drug development and commercialization teams • Coordination and integration of non-clinical, pharmaceutical, clinical development, regulatory, medical affairs and marketing strategies • Support of the IPL in project evaluation for early-stage projects (phase I and II) • Secretary of the Oncology Therapeutic Area Leadership Team responsible for coordinating and monitoring leadership team activities

• Design, execution and interpretation of clinical studies that comprised the HCV clinical development plan • Development of content for regulatory submissions such as CSRs, SCE, SCS, and draft labels • Part of the PMO development team and lead for development of neurocognitive clinical development plan for interferon-free regimens • Collaboration with marketing and market access colleagues on numerous tactical and strategic projects pertaining to market access and pricing

• Development and execution of Global Medical Communications strategy for HCV • Medical Affairs representative on HCV Market Access Strategy Development Team • Contribution to numerous clinical development and medical affairs activities beyond communications

• Integral part of brand teams for the BMS HIV portfolio involved in all aspects from strategic brand planning to execution • Close alignment with brand leads on the development of medical education strategy and tactical plans in the highly competitive field of HIV • Management and chairing of advisory boards set up to shape commercial strategy

• Responsible for medical engagement with key UK sites including the largest HIV centre in Europe • Supporting clinical development activities including site and PI selection, protocol feasibility assessments and site visits • Collaboration with KOLs on investigator sponsored clinical trials • Development of the UK HIV medical affairs plan and member of brand teams for key brands

• Development and execution of communication and publication strategies and tactics up to and beyond the launch of Baraclude (for the treatment of chronic HBV infection)

Biochemical Characterisation of Powassan Virus NS3 and the Development of Antibody-Based Inhibitors of HCV NS3